NASDAQ:CNCR Range Cancer Therapeutics ETF (CNCR) Price, Holdings, & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$15.54▼$15.9150-Day Range$27.45▼$32.2552-Week Range$25.99▼$35.82Volume3,844 shsAverage Volume6,668 shsMarket Capitalization$18.67 millionAssets Under Management$14.30 millionDividend Yield1.83%Net Expense Ratio0.79% Stock AnalysisStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestTrendsStock AnalysisDividendHeadlinesHoldingsRatingsShort InterestTrends Get Range Cancer Therapeutics ETF alerts: Email Address About Range Cancer Therapeutics ETFThe Loncar Cancer Immunotherapy ETF (CNCR) is an exchange-traded fund that is based on the Loncar Cancer Immunotherapy index. The fund tracks an equal-weighted index of companies currently producing or in clinical trials for cancer immunotherapy drugs. CNCR was launched on Oct 13, 2015 and is managed by Loncar.Read More Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here CNCR ETF News HeadlinesMay 23, 2024 | msn.comTango Therapeutics Shuts Early-Stage Cancer Study Due To Liver ToxicityMay 14, 2024 | seekingalpha.comIntensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology DrugJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 10, 2024 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Position Support Buy Rating for Context TherapeuticsMay 7, 2024 | markets.businessinsider.comRing Therapeutics Presents New Data on Anellogy™ Platform at the 27th Annual American Society of Gene & Cell Therapy ConferenceMay 6, 2024 | markets.businessinsider.comBuy Rating for CytomX Therapeutics on Promising CX-904 Probody Therapy ProspectsMarch 15, 2024 | msn.comLarge-scale study explores genetic link between colorectal cancer and meat intakeMarch 11, 2024 | markets.businessinsider.comMicrobix Unveils Test Controls for Head and Neck CancerJuly 26, 2024 | American Hartford Gold Group (Ad)Dave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.March 3, 2024 | nasdaq.comThe Zacks Analyst Blog Highlights CRPT, CNCR, WISE, AIRR and PKBSee More Headlines Receive CNCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Range Cancer Therapeutics ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerExchange Traded Concepts Fund NameRange Cancer Therapeutics ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:CNCR Inception Date10/13/2015 Fund ManagerDenise M. Krisko WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkRange Cancer Therapeutics Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings76 Fund Statistics Assets Under Management$14.30 million Average Daily Volume$8,784.00 Discount/Premium-0.10% Administrator, Advisor and Custodian AdministratorU.S. Bancorp Fund Services, LLC AdvisorExchange Traded Concepts, LLC CustodianU.S. Bank, N.A. DistributorQuasar Distributors, LLC Transfer AgentU.S. Bank, N.A. TrusteeN/A Lead Market MakerJane Street Options OptionableN/A Short Interest7,000 shs Miscellaneous Outstanding Shares1,180,000Beta1.36 Creation Unit50,000 Creation Fee$150.00 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. Range Cancer Therapeutics ETF ExpensesTypeCNCRHealth Care ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.79%0.56%0.54%0.48%0.51%Other Expenses0.00%0.33%0.50%0.39%0.54%Total Expense0.79%0.70%0.70%0.61%0.71%Fee Waiver0.00%-0.45%-0.54%-0.32%-0.59%Net Expense0.79%0.61%0.60%0.54%0.59% Range Cancer Therapeutics ETF (CNCR) Holdings & ExposureTop 10 CNCR HoldingsGeron(NASDAQ:GERN)Holding Weight: 3.79%Summit Therapeutics(NASDAQ:SMMT)Holding Weight: 2.92%Enliven Therapeutics(NASDAQ:ELVN)Holding Weight: 2.78%iTeos Therapeutics(NASDAQ:ITOS)Holding Weight: 2.16%Nurix Therapeutics(NASDAQ:NRIX)Holding Weight: 2.14%Acrivon Therapeutics(NASDAQ:ACRV)Holding Weight: 2.12%Erasca(NASDAQ:ERAS)Holding Weight: 2.06%Nuvation Bio(NYSE:NUVB)Holding Weight: 2.06%Revolution Medicines(NASDAQ:RVMD)Holding Weight: 2.05%Blueprint Medicines(NASDAQ:BPMC)Holding Weight: 1.84%CNCR Sector ExposureCNCR Industry ExposureFull Holdings Details Similar ETFsPrincipal Healthcare Innovators ETFNASDAQ:BTECHorizon Kinetics Medical ETFNASDAQ:MEDXFirst Trust Nasdaq Pharmaceuticals ETFNASDAQ:FTXHJPMorgan Healthcare Leaders ETFNASDAQ:JDOCProShares UltraShort Nasdaq BiotechnologyNASDAQ:BIS CNCR ETF - Frequently Asked Questions What other stocks do shareholders of Range Cancer Therapeutics ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Range Cancer Therapeutics ETF investors own include Micron Technology (MU), Intel (INTC), Inovio Pharmaceuticals (INO), Pfizer (PFE), Gilead Sciences (GILD) and Mastercard (MA). This page (NASDAQ:CNCR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Range Cancer Therapeutics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Range Cancer Therapeutics ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNCR Stock Alerts